(Q39346965)
Statements
Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions (English)
Murray J Towle
Kenichi Nomoto
Makoto Asano
Yoshito Kishi
Melvin J Yu
Bruce A Littlefield